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Atrial fibrillation (AF) is the most common chronic arrhyth-
mia, and its incidence and prevalence are expected to double
within the forthcoming decades [1–3]. Currently, approxi-
mately 250,000 patients have AF in the Netherlands,
corresponding to a prevalence of 5.5% in patients older than
55 years [4]. The vast majority of those patients can effec-
tively be treated with pharmacological rate or rhythm con-
trol. However, there is a small subset of patients that remains
severely symptomatic despite treatment with class 1 or 3
antiarrhythmic drugs. For those patients, an invasive approach
can be indicated [5, 6].
Historically, this means either a classic Cox-Maze 3
operation or a catheter isolation of the pulmonary veins.
The Maze operation, although associated with impressive
success rates in some centres, has been abandoned as stand-
alone procedure because of its surgical complexity and the
requirement of cardiopulmonary bypass. Catheter ablation
for atrial fibrillation is less invasive and is being performed
by an increasing number of operators and centres. The
procedure has a lower efficacy, particularly in patients with
persistent AF or an enlarged left atrium. Moreover, patients
are frequently not free of AF after a single procedure, and
more than one procedure might therefore be required. In a
recent meta analysis, the single procedure success of cathe-
ter ablation for AF was 57%, which rose to 71% after
multiple procedures in selected patients [7]. The 5-year
freedom of AF rates from Bordeaux, one of the most
esteemed AF ablation centres in the world, were 29% after
a single procedure (40% after one year), which increased to
63% after up to 7 procedures [8]. The volume of the number
of catheter ablations for AF in comparison with the number
of patients with AF is limited: approximately 2200 catheter
ablations for AF were performed in the Netherlands in 2010
(exact data from two centres missing, S.A.I.P. Trines, per-
sonal communication), accounting for less than 1% of the
number of patients with AF [4].
Bearing this in mind, a thoracoscopic surgical approach
toward pulmonary vein isolation was developed in an effort
to combine the efficacy reported with surgical ablation with
a less invasive approach. There are several small studies
showing the feasibility and safety of thoracoscopic pulmo-
nary vein isolation, and a recent systematic review demon-
strates that absence of AF recurrence (without the use of
antiarrhythmic drugs) is 79% in paroxysmal AF and 69% in
persistent AF after a single procedure in the studies pub-
lished so far [9]. The number of patients and the number of
studies are low, but there also seems to be a tendency toward
better outcomes when the procedures are performed in a
hybrid fashion, that is, by a surgeon and electrophysiologist
together. Data from Maastricht and from our own hospital
show that in a mixed population of patients with paroxysmal
and persistent AF 83 and 86%, respectively, are free of AF
without the use of antiarrhythmic drugs one year after the
procedure [9–11]. This suggests that a hybrid procedure,
where the ablation lines are controlled for conduction block
during the procedure, is associated with less AF recurrence.
Thoracoscopic or minimal invasive surgery for AF has not
been established in the Guidelines as a ‘reasonable alternative’
for either antiarrhythmic drugs or catheter ablation, which
might be due to the limited availability of published evidence.
The most recent European Society of Cardiology (ESC)
Guidelines for AF award a 2B recommendation for stand-
alone minimally invasive surgery for AF only for patients
with a previously failed catheter ablation [5]. The 2007 Heart
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Rhythm Society (HRS)/European Heart Rhythm Association
(EHRA)/European Cardiac Arrhythmia Society (ECAS) Con-
sensus provides three recommendations: surgery for AF can
be considered in patients with a failed catheter ablation, in
those with a contraindication for catheter ablation and in
patients with a preference for surgery [6].
Therefore, investigators from Nieuwegein and Barcelona
conducted the FAST study, a two-centre randomised trial,
which was published in the first 2012 issue of Circulation.
[12] The study included 124 patients (81% male, mean age
56 years) with a previously failed catheter ablation (67%) or
with enlarged atria (>40 mm in the presence of hyperten-
sion, or >45 mm without hypertension, 33%). Patients were
randomised to a redo catheter ablation or to a totally thor-
acoscopic surgical ablation, which consisted of pulmonary
vein isolation with a bipolar clamp device with or without
the addition of left atrial lines, constructed anatomically with
a bipolar cooled rail device at the discretion of the operator.
Exclusion criteria included left atrium size >65 mm, left
ventricular ejection fraction <45%, valvular disease, myo-
cardial infarction, cardiac catheter or surgical procedures in
the previous 3 months.
Atrial fibrillation was paroxysmal in 65% and persistent
or long-standing persistent in the remainder. Follow-up was
performed at 3, 6 and 12 months following the procedure
with a 7-day Holter after 6 and 12 months. After one year of
follow-up, atrial fibrillation was absent (without the use of
antiarrhythmic drugs) in 36.5% of patients who underwent
catheter ablation versus 65.6% of patients undergoing thor-
acoscopic surgery. The percentages were, of course, higher
when the use of antiarrhythmic drugs was not taken into
account: 42.9% for the catheter ablation group and 78.7%
for the surgical ablation group.
The number of adverse events was similar between the
two groups during follow-up, but there were significantly
more periprocedural complications in the surgery group
versus the catheter group. The most common complications
were directly related to the nature of the surgical procedure:
a pneumothorax occurred in six patients, a haematothorax in
one, there was one sternotomy for bleeding and one pneu-
monia. Two patients in the surgical group received a pace-
maker versus none in the catheter group. On the other hand,
in each group one patient suffered from a transient ischae-
mic attack and one from pericardial effusion/tamponade.
The FAST trial sheds new light on the invasive treatment
of AF by performing the first head-to-head comparison
between catheter ablation and surgical ablation in patients
with a previously failed catheter ablation or enlarged left
atrium with or without hypertension. The study makes it
clear that in this population surgical ablation of AF is clearly
more effective than catheter ablation. The increase in effi-
cacy, however, goes at the cost of more periprocedural
complications. Most complications reported, however, were
transient in nature, and it can be debated whether a pneu-
mothorax should be counted as a complication at all in a
procedure that relies on bilateral collapse of the lungs. It can
be expected that the complication rate will fall with increas-
ing operator experience [12].
With regard to the disappointing efficacy of catheter abla-
tion, it should be noted that this was not a standardAF ablation
population. At best, it could be considered the worst half of
AF ablation patients since all patients had failed to respond to
catheter ablation at least once before. On the other hand,
before the index procedure, two-thirds of the patients had
normal sized left atria and atrial fibrillation was paroxysmal
in two-thirds. These factors are associated with a favourable
outcome both for catheter ablation and for surgical ablation.
Should all patients with AF now be referred to the sur-
geon? It is really too early to tell, but it seems justified to
apply HRS consensus criteria and take patient preference
into account when deciding on an invasive approach. The
FAST-2 study (NCT01336075) that randomises patients
with paroxysmal AF between catheter and surgical ablation
as first-line therapy is ongoing, and will further delineate the
position of thoracoscopic surgery for AF.
The conclusions of the FAST study have not entered the
Guidelines yet, but the scope on invasive treatment of AF
has now become wider, and thoracoscopic surgery might
prove a valuable alternative for catheter ablation, particularly
for those patients who failed catheter ablation before.
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